Ewha Med J.  1997 Jun;20(2):145-149. 10.12771/emj.1997.20.2.145.

A Case of Ticlopidine-Induced Cholastatic Jaundice

• Woo KE
• Cho HK
• Shin GJ

• KMID: 1964769
• DOI: http://doi.org/10.12771/emj.1997.20.2.145

Abstract

Ticlopidine, a platelet aggregation inhibitor, is widely used in the secondary prevention of stroke and previous manifestation of peripheral arterial occlusive disease, Ticlopidine is also used to prevent myocardial infarction and post-stenting occlusion after intracoronary stent implantation. The exact mechanism of action of ticlopidine is unclear, but likely involves the inhibition of platelet activity by the suppression of adenosine diphosphate-induced patelet aggregation. The most common adverse effects are gastrointestinal problems, skin reactions, and hematologist changes. The adverse hepatic effects are not frequent(4% in different series). We experienced a case of ticlopidine-induced cholastatic jaundice, and report with review of literatures.

Keyword

Ticlopidine(Ticlid(R)); Cholastatic jaundice; Acute myocardial infarction

MeSH Terms

Adenosine
Arterial Occlusive Diseases
Blood Platelets
Jaundice*
Myocardial Infarction
Platelet Aggregation
Secondary Prevention
Skin
Stents
Stroke
Ticlopidine
Adenosine
Ticlopidine